Targeted Therapy
Approved for: NSCLC
Biomarker: EGFR, ALK

Ramucirumab (Cyramza) is a FDA-approved Targeted Therapy for non-small cell lung cancer (NSCLC) with the biomarker EGFR or ALK that has metastasized.

It is used:

  • With docetaxel in patients whose disease has gotten worse during or after treatment with platinum chemotherapy.
  • For patients whose disease has a mutation in the EGFR gene or ALK gene, ramucirumab is used if their disease has gotten worse after treatment with FDA-approved therapy for these mutations.